These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

238 related articles for article (PubMed ID: 30796464)

  • 21. Genetic polymorphisms of the adenosine triphosphate-binding cassette transporters (ABCG2, ABCB1) and gefitinib toxicity.
    Tamura M; Kondo M; Horio M; Ando M; Saito H; Yamamoto M; Horio Y; Hasegawa Y
    Nagoya J Med Sci; 2012 Feb; 74(1-2):133-40. PubMed ID: 22515119
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Genetic variation in platinating agent and taxane pathway genes as predictors of outcome and toxicity in advanced non-small-cell lung cancer.
    Lamba JK; Fridley BL; Ghosh TM; Yu Q; Mehta G; Gupta P
    Pharmacogenomics; 2014; 15(12):1565-74. PubMed ID: 25340731
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Predictive value of ABCB1 polymorphisms G2677T/A, C3435T, and their haplotype in small cell lung cancer patients treated with chemotherapy.
    Knez L; Košnik M; Ovčariček T; Sadikov A; Sodja E; Kern I; Cufer T
    J Cancer Res Clin Oncol; 2012 Sep; 138(9):1551-60. PubMed ID: 22543673
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Predictive effects of ERCC1 and XRCC3 SNP on efficacy of platinum-based chemotherapy in advanced NSCLC patients.
    Zhou C; Ren S; Zhou S; Zhang L; Su C; Zhang Z; Deng Q; Zhang J
    Jpn J Clin Oncol; 2010 Oct; 40(10):954-60. PubMed ID: 20462983
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A phase II study of irinotecan and carboplatin in advanced non-small cell lung cancer with pharmacogenomic analysis: final report.
    Pillot GA; Read WL; Hennenfent KL; Marsh S; Gao F; Viswanathan A; Cummings K; McLeod HL; Govindan R
    J Thorac Oncol; 2006 Nov; 1(9):972-8. PubMed ID: 17409981
    [TBL] [Abstract][Full Text] [Related]  

  • 26. High dose methotrexate in adult Egyptian patients with hematological malignancies: impact of ABCB1 3435C > T rs1045642 and MTHFR 677C > T rs1801133 polymorphisms on toxicities and delayed elimination.
    Ebid AIM; Hossam A; El Gammal MM; Soror S; Mangoud NOM; Mahmoud MA
    J Chemother; 2022 Oct; 34(6):381-390. PubMed ID: 34895107
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effects of the ABCB1 c.3435C>T (rs1045642) Polymorphism on Heat Pain Perception in Opioid-Free Adults With Chronic Pain.
    Hooten WM; Hu D; Cunningham JM
    Anesth Analg; 2021 Oct; 133(4):1028-1035. PubMed ID: 34153010
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Association of ERCC1-C118T and -C8092A polymorphisms with lung cancer risk and survival of advanced-stage non-small cell lung cancer patients receiving platinum-based chemotherapy: a pooled analysis based on 39 reports.
    Xu TP; Shen H; Liu LX; Shu YQ
    Gene; 2013 Sep; 526(2):265-74. PubMed ID: 23727606
    [TBL] [Abstract][Full Text] [Related]  

  • 29. XPC Lys939Gln polymorphism is associated with the decreased response to platinum based chemotherapy in advanced non-small-cell lung cancer.
    Zhu XL; Sun XC; Chen BA; Sun N; Cheng HY; Li F; Zhang HM; Feng JF; Qin SK; Cheng L; Lu ZH
    Chin Med J (Engl); 2010 Dec; 123(23):3427-32. PubMed ID: 22166526
    [TBL] [Abstract][Full Text] [Related]  

  • 30. The relationship between polymorphisms of genes regulating DNA repair or cell division and the toxicity of platinum and vinorelbine chemotherapy in advanced NSCLC patients.
    Powrózek T; Mlak R; Krawczyk P; Homa I; Ciesielka M; Kozioł P; Prendecka M; Milanowski J; Małecka-Massalska T
    Clin Transl Oncol; 2016 Feb; 18(2):125-31. PubMed ID: 26193985
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Influence of polymorphisms in MTHFR 677 C→T, TYMS 3R→2R and MTR 2756 A→G on NSCLC risk and response to platinum-based chemotherapy in advanced NSCLC.
    Cui LH; Yu Z; Zhang TT; Shin MH; Kim HN; Choi JS
    Pharmacogenomics; 2011 Jun; 12(6):797-808. PubMed ID: 21605004
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Polymorphisms of p53 and MDM2 genes are associated with severe toxicities in patients with non-small cell lung cancer.
    Zheng D; Chen Y; Gao C; Wei Y; Cao G; Lu N; Hou Y; Jiang X; Wang J
    Cancer Biol Ther; 2014; 15(11):1542-51. PubMed ID: 25482940
    [TBL] [Abstract][Full Text] [Related]  

  • 33. MRP2 and GSTP1 polymorphisms and chemotherapy response in advanced non-small cell lung cancer.
    Sun N; Sun X; Chen B; Cheng H; Feng J; Cheng L; Lu Z
    Cancer Chemother Pharmacol; 2010 Feb; 65(3):437-46. PubMed ID: 19568750
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Genetic polymorphisms affecting clinical outcomes in epithelial ovarian cancer patients treated with taxanes and platinum compounds: a Korean population-based study.
    Kim HS; Kim MK; Chung HH; Kim JW; Park NH; Song YS; Kang SB
    Gynecol Oncol; 2009 May; 113(2):264-9. PubMed ID: 19203783
    [TBL] [Abstract][Full Text] [Related]  

  • 35. ABCB1 polymorphism predicts the toxicity and clinical outcome of lung cancer patients with taxane-based chemotherapy.
    Zhong J; Guo Z; Fan L; Zhao X; Zhao B; Cao Z; Cheng L; Shi Y; Li X; Zhang Y; An T; Wu M; Wang Y; Zhuo M; Li J; Yang X; Chen H; Jia B; Zhao J
    Thorac Cancer; 2019 Nov; 10(11):2088-2095. PubMed ID: 31571407
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Variations within 3'-UTR of MDM4 gene contribute to clinical outcomes of advanced non-small cell lung cancer patients following platinum-based chemotherapy.
    Yang Y; Gao W; Ding X; Xu W; Liu D; Su B; Sun Y
    Oncotarget; 2017 Mar; 8(10):16313-16324. PubMed ID: 27462918
    [TBL] [Abstract][Full Text] [Related]  

  • 37. PTEN polymorphisms contribute to clinical outcomes of advanced lung adenocarcinoma patients treated with platinum-based chemotherapy.
    Yang Y; Xu W; Liu D; Ding X; Su B; Sun Y; Gao W
    Tumour Biol; 2016 Jun; 37(6):7785-96. PubMed ID: 26695147
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Pharmacogenetic analysis of advanced non-small-cell lung cancer patients treated with first-line paclitaxel and carboplatin chemotherapy.
    Park HS; Lim SM; Shin HJ; Cho A; Shin JG; Lee MG; Kim HR; Kim JH; Cho BC
    Pharmacogenet Genomics; 2016 Mar; 26(3):116-25. PubMed ID: 26641474
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Association of MDR1 and ERCC1 polymorphisms with response and toxicity to cisplatin-based chemotherapy in non-small-cell lung cancer patients.
    Chen S; Huo X; Lin Y; Ban H; Lin Y; Li W; Zhang B; Au WW; Xu X
    Int J Hyg Environ Health; 2010 Mar; 213(2):140-5. PubMed ID: 20189873
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Genetic variation in DNA polymerase kappa gene is associated with the prognosis after platinum-based chemotherapy in small cell lung cancer patients].
    Chen JN; Feng T; Yang J; Li HM; Yuan P; Ma F; Yin LL; Lin DX; Xu BH; Tan W
    Zhonghua Zhong Liu Za Zhi; 2019 Feb; 41(2):112-117. PubMed ID: 30862140
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.